Cargando…

Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?

BACKGROUND: The impact on survival of complete resection (CR) in patients with malignant glioma and MGMT promoter methylation on adjuvant therapy strategies has been proven in the past. However, it is not known whether a MGMT promoter methylation can compensate a subtotal resection. Therefore, we an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mareike, Müller, Franziska, Staub-Bartelt, Julia, Ehrmann, Daniel, Hänggi, Michael, Sabel, Jörg, Felsberg, Marion, Rapp
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279995/ https://www.ncbi.nlm.nih.gov/pubmed/34185258 http://dx.doi.org/10.1007/s11060-021-03794-8

Ejemplares similares

Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide
por: Berger, Kerstin, et al.
Publicado: (2020)

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
por: Radke, Josefine, et al.
Publicado: (2019)

The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma
por: Incekara, Fatih, et al.
Publicado: (2020)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2020)

Resection of Eloquent Located Brain Tumors by Mapping Only—A Feasibility Study
por: Staub-Bartelt, Franziska, et al.
Publicado: (2023)

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
por: Incekara, Fatih, et al.
Publicado: (2020)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

Impact of Anticipated Awake Surgery on Psychooncological Distress in Brain Tumor Patients
por: Staub-Bartelt, Franziska, et al.
Publicado: (2022)

Functional Outcome and Overall Survival in Patients with Primary or Secondary CNS Lymphoma after Surgical Resection vs. Biopsy
por: Staub-Bartelt, Franziska, et al.
Publicado: (2023)

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
por: Diplas, Bill H., et al.
Publicado: (2018)

Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement
por: Rosen, Jurij, et al.
Publicado: (2021)

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

Impact of COVID-19 Epidemic on Psycho-Oncological Distress in Neuro-Oncological Patients
por: Staub-Bartelt, Franziska, et al.
Publicado: (2022)

The Influence of Gene Aberrations on Survival in Resected IDH Wildtype Glioblastoma Patients: A Single-Institution Study
por: Kalita, Ondrej, et al.
Publicado: (2021)

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
por: Teske, Nico, et al.
Publicado: (2021)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[(18)F]-fluoroethyl)-l-tyrosine PET
por: Bauer, Elena K., et al.
Publicado: (2020)

Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status
por: Unger, Kristian, et al.
Publicado: (2020)

Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
por: Liu, Elisa K, et al.
Publicado: (2022)

ADC, D, f dataset calculated through the simplified IVIM model, with MGMT promoter methylation, age, and ECOG, in 38 patients with wildtype IDH glioblastoma
por: Maralani, Pejman Jabehdar, et al.
Publicado: (2021)

GEN-13 FIREWORK PATTERN OF CANCER GENESIS FOR GLIOBLASTOMA, IDH-WILDTYPE
por: Yoon, Seon-Jin, et al.
Publicado: (2019)

Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses
por: Liu, Yu-Qing, et al.
Publicado: (2019)

Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma
por: Saaid, Ayoub, et al.
Publicado: (2022)

Feasibility, Safety and Impact on Overall Survival of Awake Resection for Newly Diagnosed Supratentorial IDH-Wildtype Glioblastomas in Adults
por: Moiraghi, Alessandro, et al.
Publicado: (2021)

Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma
por: Jungk, Christine, et al.
Publicado: (2019)

Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres
por: Yoon, Seon-Jin, et al.
Publicado: (2020)

Glioblastoma, IDH-wildtype: A New Association with IgM Paraproteinaemic Neuropathy?
por: Lewis, Dana M., et al.
Publicado: (2022)

Glioblastoma, IDH-wildtype with leptomeningeal metastasis to Meckel’s cave: A case report
por: Murata, Toshiki, et al.
Publicado: (2022)

Initial Treatment of IDH-Wildtype Glioblastoma in Adults Older Than 70 Years
por: Bao, Jing, et al.
Publicado: (2023)

Distribution and favorable prognostic implication of genomic EGFR alterations in IDH ‐wildtype glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions
por: Mata, Douglas A., et al.
Publicado: (2020)

MPC-02 Prognostic effects of molecular factors in elderly patients with IDH-wildtype Glioblastomas
por: Fukai, Junya, et al.
Publicado: (2020)

Newly Diagnosed IDH-Wildtype Glioblastoma and Temporal Muscle Thickness: A Multicenter Analysis
por: Wende, Tim, et al.
Publicado: (2021)

EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome
por: da Costa, Bruno Henrique Bressan, et al.
Publicado: (2022)

Pleiotropy of PP2A Phosphatases in Cancer with a Focus on Glioblastoma IDH Wildtype
por: Kashani, Elham, et al.
Publicado: (2022)

Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib
por: Lawson McLean, Aaron
Publicado: (2023)

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
por: Yang, Pei, et al.
Publicado: (2015)

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
por: Marchi, Francesco, et al.
Publicado: (2020)

Survival Benefit of Supratotal Resection in a Long-term Survivor of IDH-wildtype Glioblastoma: A Case Report and Literature Review
por: YAMAGUCHI, Junya, et al.
Publicado: (2021)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_82uo4m13m0tvkmsa7umok8n0pr